Hamed Alavi - 18 Jan 2023 Form 3 Insider Report for enVVeno Medical Corp (NVNO)

Role: Chief Technology Officer
Signature: /s/ Hamed Alavi
Issuer symbol: NVNO
Transactions as of: 18 Jan 2023
Net transactions value: $0
Form type: 3
Filing time: 31 Jan 2023, 20:56:22 UTC
Next filing: 07 Dec 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NVNO	Stock Options							18 Jan 2023	Common Stock	100,000	$6.70	Direct	F1
holding	NVNO	Stock Options							18 Jan 2023	Common Stock	125,925	$6.70	Direct	F2
holding	NVNO	Stock Options							18 Jan 2023	Common Stock	320,000	$8.20	Direct	F3
holding	NVNO	Stock Options							18 Jan 2023	Common Stock	8,000	$10.00	Direct	F4
holding	NVNO	Restricted Stock Unit							18 Jan 2023	Common Stock	50,000		Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2025.
F2	The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024.
F3	The common stock options were issued to the Reporting Person on February 18, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through March 2024.
F4	The common stock options were issued to the Reporting Person on July 18, 2020 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through September 2023.
F5	The Reporting Person was granted 50,000 restricted stock units on November 30, 2021 pursuant to the Plan. The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve.